JP2007508386A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007508386A5 JP2007508386A5 JP2006535571A JP2006535571A JP2007508386A5 JP 2007508386 A5 JP2007508386 A5 JP 2007508386A5 JP 2006535571 A JP2006535571 A JP 2006535571A JP 2006535571 A JP2006535571 A JP 2006535571A JP 2007508386 A5 JP2007508386 A5 JP 2007508386A5
- Authority
- JP
- Japan
- Prior art keywords
- represented
- use according
- structural formula
- nhcor
- conhr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101000685982 Homo sapiens NAD(+) hydrolase SARM1 Proteins 0.000 claims 40
- 102100023356 NAD(+) hydrolase SARM1 Human genes 0.000 claims 40
- 239000000849 selective androgen receptor modulator Substances 0.000 claims 40
- 150000001875 compounds Chemical class 0.000 claims 39
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 35
- 239000000126 substance Substances 0.000 claims 35
- 125000000217 alkyl group Chemical group 0.000 claims 30
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 20
- 125000004122 cyclic group Chemical group 0.000 claims 20
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 15
- 101100149678 Caenorhabditis elegans snr-3 gene Proteins 0.000 claims 15
- 125000004982 dihaloalkyl group Chemical group 0.000 claims 15
- 125000001188 haloalkyl group Chemical group 0.000 claims 15
- 125000004385 trihaloalkyl group Chemical group 0.000 claims 15
- 210000000988 bone and bone Anatomy 0.000 claims 11
- 125000003342 alkenyl group Chemical group 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 230000003054 hormonal effect Effects 0.000 claims 6
- 102000007399 Nuclear hormone receptor Human genes 0.000 claims 5
- 108020005497 Nuclear hormone receptor Proteins 0.000 claims 5
- 125000004948 alkyl aryl alkyl group Chemical group 0.000 claims 5
- 102000001307 androgen receptors Human genes 0.000 claims 5
- 108010080146 androgen receptors Proteins 0.000 claims 5
- 229910052760 oxygen Inorganic materials 0.000 claims 5
- 229910052717 sulfur Inorganic materials 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 4
- WSNMPAVSZJSIMT-UHFFFAOYSA-N COc1c(C)c2COC(=O)c2c(O)c1CC(O)C1(C)CCC(=O)O1 Chemical compound COc1c(C)c2COC(=O)c2c(O)c1CC(O)C1(C)CCC(=O)O1 WSNMPAVSZJSIMT-UHFFFAOYSA-N 0.000 claims 3
- 208000001132 Osteoporosis Diseases 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 206010003591 Ataxia Diseases 0.000 claims 2
- 230000037118 bone strength Effects 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 230000009245 menopause Effects 0.000 claims 2
- 230000001009 osteoporotic effect Effects 0.000 claims 2
- 208000006386 Bone Resorption Diseases 0.000 claims 1
- 208000029725 Metabolic bone disease Diseases 0.000 claims 1
- 206010049088 Osteopenia Diseases 0.000 claims 1
- 230000024279 bone resorption Effects 0.000 claims 1
- 230000001054 cortical effect Effects 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000011707 mineral Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 0 C*C(*(*)*(C)CC=*1)=C1NC Chemical compound C*C(*(*)*(C)CC=*1)=C1NC 0.000 description 5
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51013803P | 2003-10-14 | 2003-10-14 | |
| US61320604P | 2004-09-28 | 2004-09-28 | |
| PCT/US2004/033395 WO2005037201A2 (en) | 2003-10-14 | 2004-10-12 | Treating bone-related disorders with selective androgen receptor modulators |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010212921A Division JP2010280733A (ja) | 2003-10-14 | 2010-09-23 | 選択的アンドロゲン受容体調節剤による骨関連疾患の治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007508386A JP2007508386A (ja) | 2007-04-05 |
| JP2007508386A5 true JP2007508386A5 (cg-RX-API-DMAC7.html) | 2007-07-19 |
Family
ID=34467965
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006535571A Pending JP2007508386A (ja) | 2003-10-14 | 2004-10-12 | 選択的アンドロゲン受容体調節剤による骨関連疾患の治療 |
| JP2010212921A Pending JP2010280733A (ja) | 2003-10-14 | 2010-09-23 | 選択的アンドロゲン受容体調節剤による骨関連疾患の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010212921A Pending JP2010280733A (ja) | 2003-10-14 | 2010-09-23 | 選択的アンドロゲン受容体調節剤による骨関連疾患の治療 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20060019931A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2476415A3 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2007508386A (cg-RX-API-DMAC7.html) |
| CN (1) | CN101721402B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2004281708B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2535953C (cg-RX-API-DMAC7.html) |
| EA (1) | EA013738B1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL172043A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MXPA06002462A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2005037201A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8853266B2 (en) | 2001-12-06 | 2014-10-07 | University Of Tennessee Research Foundation | Selective androgen receptor modulators for treating diabetes |
| US20070161608A1 (en) * | 2001-12-06 | 2007-07-12 | Dalton James T | Selective androgen receptor modulators for treating muscle wasting |
| US20060276539A1 (en) * | 2002-10-16 | 2006-12-07 | Dalton James T | Treating Androgen Decline in Aging Male (ADAM)- associated conditions with SARMS |
| CA2501874A1 (en) * | 2002-10-16 | 2004-04-29 | Gtx, Inc. | Treating androgen decline in aging male (adam)-associated conditions with sarms |
| US8309603B2 (en) | 2004-06-07 | 2012-11-13 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
| US20110237664A1 (en) * | 2004-06-07 | 2011-09-29 | Dalton James T | Selective androgen receptor modulators for treating diabetes |
| PL1753417T3 (pl) * | 2004-06-07 | 2012-09-28 | Univ Tennessee Res Found | Selektywny modulator receptora androgenowego i jego zastosowania medyczne |
| US9884038B2 (en) | 2004-06-07 | 2018-02-06 | University Of Tennessee Research Foundation | Selective androgen receptor modulator and methods of use thereof |
| US9889110B2 (en) | 2004-06-07 | 2018-02-13 | University Of Tennessee Research Foundation | Selective androgen receptor modulator for treating hormone-related conditions |
| DK2038252T3 (en) * | 2006-07-12 | 2016-12-19 | Univ Tennessee Res Found | SUBSTITUTED AND ACYLANILIDER methods of use thereof |
| US9844528B2 (en) | 2006-08-24 | 2017-12-19 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
| EP3056483A1 (en) * | 2006-08-24 | 2016-08-17 | University of Tennessee Research Foundation | Substituted acylanilides and methods of use thereof |
| US9730908B2 (en) | 2006-08-24 | 2017-08-15 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
| US10010521B2 (en) | 2006-08-24 | 2018-07-03 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
| PL2205552T3 (pl) * | 2007-09-11 | 2018-07-31 | Gtx, Inc. | Krystaliczny polimorf selektywnych modulatorów receptora androgenowego (R) lub (S)-N-(4-cyjano-3-(trifluorometylo)fenylo)-3-(4-cyjanofenoksy)-2-hydroksy-2-metylopropanamidu |
| US7968603B2 (en) | 2007-09-11 | 2011-06-28 | University Of Tennessee Research Foundation | Solid forms of selective androgen receptor modulators |
| US8395552B2 (en) | 2010-11-23 | 2013-03-12 | Metamagnetics, Inc. | Antenna module having reduced size, high gain, and increased power efficiency |
| WO2013152170A1 (en) * | 2012-04-04 | 2013-10-10 | Catylix, Inc. | Selective androgen receptor modulators |
| US10987334B2 (en) | 2012-07-13 | 2021-04-27 | University Of Tennessee Research Foundation | Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs) |
| US9969683B2 (en) | 2012-07-13 | 2018-05-15 | Gtx, Inc. | Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS) |
| US10314807B2 (en) | 2012-07-13 | 2019-06-11 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
| US10258596B2 (en) | 2012-07-13 | 2019-04-16 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
| US9744149B2 (en) | 2012-07-13 | 2017-08-29 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
| US9622992B2 (en) | 2012-07-13 | 2017-04-18 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
| HUE052574T2 (hu) | 2012-07-13 | 2021-05-28 | Oncternal Therapeutics Inc | Eljárás mellrákok kezelésére szelektív ösztrogén receptor modulátorral (SARM) |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LU88769I2 (fr) * | 1982-07-23 | 1996-11-05 | Zeneca Ltd | Bicalutamide et ses sels et esters pharmaceutiquement acceptables (Casodex (R)) |
| US6995284B2 (en) * | 2000-08-24 | 2006-02-07 | The University Of Tennessee Research Foundation | Synthesis of selective androgen receptor modulators |
| AU7604798A (en) * | 1997-05-30 | 1998-12-30 | University Of Tennessee Research Corporation, The | Non-steroidal agonist compounds and their use in male hormone therapy |
| US20020022026A1 (en) * | 1998-05-11 | 2002-02-21 | Paz Einat | Genes associated with mechanical stress, expression products therefrom, and uses thereof |
| AU2001288213B2 (en) * | 2000-06-28 | 2005-04-14 | Bristol-Myers Squibb Company | Selective androgen receptor modulators and methods for their identification, design and use |
| US20030232792A1 (en) * | 2000-08-24 | 2003-12-18 | Dalton James T. | Selective androgen receptor modulators and methods of use thereof |
| US7026500B2 (en) * | 2000-08-24 | 2006-04-11 | University Of Tennessee Research Foundation | Halogenated selective androgen receptor modulators and methods of use thereof |
| IL154425A0 (en) * | 2000-08-24 | 2003-09-17 | Univ Tennessee Res H Corp | Selective androgen receptor modulators and methods of use thereof |
| ATE344233T1 (de) * | 2000-08-24 | 2006-11-15 | Univ Tennessee Res Corp | Selektive modulatoren des andro genrezeptors und methoden zu deren verwendung |
| US6838484B2 (en) * | 2000-08-24 | 2005-01-04 | University Of Tennessee Research Foundation | Formulations comprising selective androgen receptor modulators |
| JPWO2002022585A1 (ja) * | 2000-09-14 | 2004-01-22 | 科研製薬株式会社 | テトラヒドロキノリン化合物 |
| US20030022868A1 (en) * | 2001-06-25 | 2003-01-30 | Dalton James T. | Selective androgen receptor modulators and methods of use thereof |
| AU2002330031B2 (en) * | 2001-09-21 | 2007-07-05 | Merck & Co., Inc. | Androstanes as androgen receptor modulators |
| DK1463497T3 (da) * | 2001-12-06 | 2012-01-30 | Gtx Inc | Behandling af muskelsvind med selektive androgenreceptormodulatorer |
| JP4677516B2 (ja) * | 2002-02-07 | 2011-04-27 | ユニバーシティ オブ テネシー リサーチ ファウンデーション | Ｓａｒｍを用いた前立腺肥大症治療 |
| CA2478186C (en) * | 2002-03-13 | 2011-08-23 | Merck & Co., Inc. | Fluorinated 4-azasteroid derivatives as androgen receptor modulators |
| US20040224979A1 (en) * | 2002-10-15 | 2004-11-11 | Dalton James T. | Treating obesity with selective androgen receptor modulators |
| CA2501874A1 (en) * | 2002-10-16 | 2004-04-29 | Gtx, Inc. | Treating androgen decline in aging male (adam)-associated conditions with sarms |
| CA2513242C (en) * | 2003-01-13 | 2013-07-09 | Gtx Inc. | Large-scale synthesis of selective androgen receptor modulators |
| CA2514024A1 (en) * | 2003-01-22 | 2004-08-05 | Gtx Inc. | Treating androgen deficiency in female (adif)-associated conditions with sarms |
-
2004
- 2004-10-12 MX MXPA06002462A patent/MXPA06002462A/es active IP Right Grant
- 2004-10-12 US US10/961,380 patent/US20060019931A1/en not_active Abandoned
- 2004-10-12 WO PCT/US2004/033395 patent/WO2005037201A2/en not_active Ceased
- 2004-10-12 CA CA2535953A patent/CA2535953C/en not_active Expired - Fee Related
- 2004-10-12 JP JP2006535571A patent/JP2007508386A/ja active Pending
- 2004-10-12 AU AU2004281708A patent/AU2004281708B2/en not_active Ceased
- 2004-10-12 CN CN2009102541735A patent/CN101721402B/zh not_active Expired - Fee Related
- 2004-10-12 EP EP12161224A patent/EP2476415A3/en not_active Withdrawn
- 2004-10-12 EP EP04809913A patent/EP1673376A4/en not_active Withdrawn
- 2004-10-12 EA EA200600228A patent/EA013738B1/ru not_active IP Right Cessation
-
2005
- 2005-11-17 IL IL172043A patent/IL172043A0/en unknown
-
2010
- 2010-09-23 JP JP2010212921A patent/JP2010280733A/ja active Pending